Video

Q&A With Dina Kao From University of Alberta: Working to 'Advance the Science' of Fecal Microbiota Transplant

Author(s):

Patients with C-Diff are being treated with fecal microbiota transplantation but there is still more research being done in the field to learn more about the potential benefits in the field.

Patients with C-Diff are being treated with fecal microbiota transplantation but there is still more research being done in the field to learn more about the potential benefits in the field.

Dina Kao, MD, from the University of Alberta was part of a team that presented the results of a study on the topic during Digestive Disease Week in Washintgon, DC. Kao said the procedure has become a common treatment option so work can now be done to see how it can be done for other conditions and helping as many patients as possible. "There's just so many unanswered questions when it comes to fecal transplant," she said.

Related Videos
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
A. Sidney Barritt, MD | Credit: UNC School of Medicine
Muthiah Vaduganathan, MD, MPH | Credit: Brigham and Women's Hospital
© 2024 MJH Life Sciences

All rights reserved.